Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes

• Main Authors: Alexander Malogolovkin, Nizami Gasanov, Alexander Egorov, Marianna Weener, Roman Ivanov, Alexander Karabelsky
• Format: Article
• Language: English
• Published: MDPI AG 2021-06-01
• Series: Viruses
• Subjects: oncolytic virus; virotherapy; immune checkpoint inhibitors; cancer immunotherapy; clinical trials; cancer gene therapy
• Online Access: https://www.mdpi.com/1999-4915/13/7/1271

Recent cancer immunotherapy breakthroughs have fundamentally changed oncology and revived the fading hope for a cancer cure. The immune checkpoint inhibitors (ICI) became an indispensable tool for the treatment of many malignant tumors. Alongside ICI, the application of oncolytic viruses in clinical trials is demonstrating encouraging outcomes. Dozens of combinations of oncolytic viruses with conventional radiotherapy and chemotherapy are widely used or studied, but it seems quite complicated to highlight the most effective combinations. Our review summarizes the results of clinical trials evaluating oncolytic viruses with or without genetic alterations in combination with immune checkpoint blockade, cytokines, antigens and other oncolytic viruses as well. This review is focused on the efficacy and safety of virotherapy and the most promising combinations based on the published clinical data, rather than presenting all oncolytic virus variations, which are discussed in comprehensive literature reviews. We briefly revise the research landscape of oncolytic viruses and discuss future perspectives in virus immunotherapy, in order to provide an insight for novel strategies of cancer treatment.